-
Mashup Score: 5Three osteoporosis risk assessment tools underperform in younger postmenopausal women - 6 day(s) ago
Three risk assessment tools struggled to detect osteoporosis based on bone mineral density T-scores among women aged 50 to 64 years, researchers reported in a study published in JAMA Network Open. Researchers assessed the performance of the Osteoporosis Self-Assessment Tool, the Osteoporosis Risk Assessment Instrument and the Osteoporosis Index of Risk, which are three of the five clinical risk
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns.In December, the FDA released a statement to health care professionals and patients warning against the use of compounded and counterfeit versions of diabetes and obesity drugs, including semaglutide (Ozempic/Wegovy, Novo
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨Endocrine Today's March Healio Exclusive is now online! Read about concerns physicians have about the safety of off-brand #obesity drugs and how the end of shortages won't entirely resolve concerns. @drard @MarsApovian @JoshuaNeumiller @GoHealio https://t.co/99raDO3P4T
-
-
Mashup Score: 4Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits - 8 day(s) ago
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported. In findings from a microsimulation model published in JAMA Health Forum, semaglutide (Wegovy, Novo Nordisk) had the highest incremental cost-effectiveness ratio (ICER) of
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💵 Despite conferring more benefits than other drugs, #semaglutide and #tirzepatide are not cost-effective treatments for #obesity due to their high net price @UChicagoMed @GoHealio @CardiologyToday https://t.co/Nqi8Pz3PQj
-
-
Mashup Score: 2
Data from the Barbara Davis Center for Diabetes at University of Colorado show pilots with type 1 diabetes are not just thriving in the air, but also with their diabetes management. In November 2019, a change to Federal Aviation Administration regulations permitted people with insulin-treated type 1 diabetes to receive first-class and second-class medical certificates, allowing adults with type 1
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
✈️ Did you know that an FAA regulation change from 2019 now allows people with type 1 #diabetes to become commercial airline pilots? Healio spoke with @drhkakturk of @CUAnschutz about what his clinic has learned about diabetes management for pilots https://t.co/DghArIC04K
-
-
Mashup Score: 4Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits - 10 day(s) ago
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported. In findings from a microsimulation model published in JAMA Health Forum, semaglutide (Wegovy, Novo Nordisk) had the highest incremental cost-effectiveness ratio (ICER) of
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💵 Despite conferring more benefits than other drugs, #semaglutide and #tirzepatide are not cost-effective treatments for #obesity due to their high net price @UChicagoMed @GoHealio @CardiologyToday https://t.co/Nqi8Pz3PQj
-
-
Mashup Score: 1Bionic pancreas for type 1 diabetes feasible to implement in primary care, telehealth - 10 day(s) ago
Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the device through an endocrinologist, researchers reported. In a small study published in Clinical Diabetes, 97% of all adults achieved a continuous glucose monitoring average glucose of less than 183 mg/dL at 2 weeks with use of the iLet
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🏥Use of the @BetaBionics iLet bionic pancreas conferred a #CGM average glucose of less than 183 mg/dL in nearly all adults with type 1 #diabetes, regardless of whether they received training from primary care or an endocrinologist. @CUAnschutz @GoHealio https://t.co/CRIZzDvUgD
-
-
Mashup Score: 3CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes - 15 day(s) ago
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial. As Healio previously reported in December, CagriSema (Novo Nordisk) conferred a 22.7% weight loss at 68 weeks among adults with obesity and without diabetes in the REDEFINE 1 trial. In
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨Topline results from the REDEFINE 2 trial revealed adults with #obesity and type 2 #diabetes lost 15.7% of their body weight at 68 weeks with once-weekly CagriSema. @novonordiskus @GoHealio @CardiologyToday https://t.co/bIjHGyPZWC
-
-
Mashup Score: 0NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain - 15 day(s) ago
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.In a March 5 press release, Novo Nordisk announced the launch of NovoCare Pharmacy, a direct-to-patient program that will provide any available dose of Wegovy (semaglutide, Novo Nordisk) for $499 per month.
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊 A new direct-to-consumer program launched by @novonordiskus will allow patients without insurance coverage for #obesity drugs to purchase #Wegovy. Healio spoke with Katherine H. Saunders, MD, DABOM, and @DianaMIsaacs about the new initiative. https://t.co/Z7FD5BTSzL
-
-
Mashup Score: 0NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain - 18 day(s) ago
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.In a March 5 press release, Novo Nordisk announced the launch of NovoCare Pharmacy, a direct-to-patient program that will provide any available dose of Wegovy (semaglutide, Novo Nordisk) for $499 per month.
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊 A new direct-to-consumer program launched by @novonordiskus will allow patients without insurance coverage for #obesity drugs to purchase #Wegovy. Healio spoke with Katherine H. Saunders, MD, DABOM, and @DianaMIsaacs about the new initiative. https://t.co/Z7FD5BTSzL
-
-
Mashup Score: 0
After rising over a 35-year period, thyroid cancer incidence in the U.S. plateaued from 2010 to 2019, according to findings published in The Lancet Diabetes & Endocrinology. In a retrospective analysis of data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) and National Center for Health Statistics databases, researchers found no changes in
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰After decades of rising #thyroid cancer incidence rates in the U.S., incidence plateaued from 2010 to 2019. However, researchers say more work is needed to reduce thyroid cancer overdiagnosis. @TheLancetEndo @HemOncToday https://t.co/3jYBYCP5uX
-
🚨Three risk assessment tools recommended by USPSTF for #osteoporosis screening had AUCs that were less than "acceptable" for women aged 50 to 64 years, researchers reported in @JAMANetworkOpen. @dgsomucla @UCLAMII @healiowomen @OrthoToday https://t.co/H4w0xUCIe6